Drugs / measles-mumps-rubella (MMR) vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03537508 | Apr 2018 → Sep 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT07312604 | Dec 2025 → Mar 2026 overdue | dermatophytosis of groin and perianal area, tinea corporis | Abeer Mohamed Abdelaziz Elkholy | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, mumps, rubella (MMR) vaccine | “Participants will receive intra-lesional immunotherapy using the measles-mumps-rubella (MMR) vaccine.” NCT07312604 ↗ |
| Modality | Vaccine | “MMR vaccine” NCT03537508 ↗ |